Related Experiment Video
Updated: Apr 8, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Evaluation of hGM-CSF/hTNFα surface-modified prostate cancer therapeutic vaccine in the huPBL-SCID chimeric mouse
Shouhua Lai1, Zhiyong Huang2, Yunting Guo3
1Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. laishouhua5211314@126.com.
Abstract:
To validate its efficacy in the context of the human immune system, a novel therapeutic vaccine of hGM-CSF/hTNFα surface-modified PC-3 cells against human prostate cancer was evaluated in the human peripheral blood lymphocytes-severe combined immunodeficiency (huPBL-SCID) chimeric mouse model. The hGM-CSF or/and hTNFα modified vaccines inhibited prostate cancer growth effectively so as to prolong the mouse survival significantly. The splenocytes from the hGM-CSF/hTNFα vaccine-inoculated mice showed the strongest tumor-specific cytotoxicity against PC-3 cells and the highest production of IFNɤ. These features indicated that type 1 protective immune response was induced efficiently against human prostate cancer and further enhanced through synergetic adjuvant effects of hGM-CSF and hTNFα.
Insights
A novel prostate cancer vaccine using modified PC-3 cells with GM-CSF and TNFα effectively inhibited tumor growth and improved survival in mice. This approach stimulates a potent type 1 immune response against human prostate cancer.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Evaluating a novel therapeutic vaccine for human prostate cancer using surface-modified PC-3 cells.
- Utilizing the human peripheral blood lymphocytes-severe combined immunodeficiency (huPBL-SCID) chimeric mouse model to assess efficacy within a human immune system context.
Discussion:
- The hGM-CSF or/and hTNFα modified vaccines demonstrated significant inhibition of prostate cancer growth.
- Vaccine inoculation led to prolonged survival in the mouse model.
- Splenocytes from vaccinated mice exhibited enhanced tumor-specific cytotoxicity against PC-3 cells.
Key Insights:
- The hGM-CSF/hTNFα vaccine induced a strong type 1 protective immune response against human prostate cancer.
- Synergistic adjuvant effects of hGM-CSF and hTNFα were observed, enhancing the immune response.
- High production of IFN-γ was noted in splenocytes from mice receiving the hGM-CSF/hTNFα vaccine.
Outlook:
- Further investigation into the synergistic mechanisms of hGM-CSF and hTNFα in cancer immunotherapy.
- Potential for this vaccine strategy in clinical applications for human prostate cancer treatment.
- Exploring the long-term efficacy and safety of this therapeutic approach.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018